CURRICULUM VITAE – *Jaume Mora*

POSITION:

Scientific director, Pediatric Cancer Center Barcelona (PCCB). Hospital Sant Joan de Déu, 2012- current
Associate member, Oncology Program; Institute for Research in Biomedicine (IRB), Barcelona, 2014- current

Education:
Faculty of Medicine, Autonomous University of Barcelona, Spain. 1995-2003, PhD
Faculty of Medicine, University of Barcelona, Spain. 1984-1990. MD.
Pediatrics Residency at Hospital Infantil de la Vall d'Hebron. Autonomous University of Barcelona. 1992-1995.
Pediatric Hematology and Oncology Clinical Fellowship.1996-1999. Joint Fellowship Program at The New York Hospital Cornell University and Memorial Sloan-Kettering Cancer Center combined programs New York, USA.
Molecular pathology of pediatric tumors Research Fellowship. 1999-2001. Special Pediatric and Molecular Pathology Fellowship program at Memorial-Sloan Kettering Cancer center, New York, NY, USA.

Honors, Grants and Awards:
2018. SIOP 2018 Schweisguth Prize "Therapeutic targeting of the Rb/E2F-1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01" to Guillem Pascual-Pastó. PI: Angel Montero. KYOTO, Japan; November 2018.
2016. Innovative Medicines initiative 2 Joint Undertaking (H2020-1M12-JTI-201 5-07) PI: Stefan Pfister. HSJD partner A. Montero-Carcaboso. EUR 7 370 000 (HSJD: 100.000). Period 2017-2021
2016. Fundació La Caixa, Projectes de la Fundació per la Recerca. Phosphoinositide 3-kinase Signalling in Oncogenic Vascular Malformations. PI:M Graupera/J Mora/ E Baselga. Dotació: 255.535 €. Period 207-2019.
2015. I Award "Martí Via" of translational research in Oncology. Grant: 30.000 €
2009. First Annual FERO Grant in Translational Oncology Research. PI: J Mora. Grant: 70.000 €.
2001 16th O. Schweisguth Prize, International Society of Pediatric Oncology. Brisbane, Australia, October 2001.
2001. ASCO Career Development Award."Gene expression analysis in neuroblastoma". Grant: $170,000.
2000. ASCO Young Investigator Award."Genetic Alterations in Neuroblastic Tumors". Grant: $35,000.

Innovation and Industrial Development:
Founder, CEBIOTEX L.S. CEB-001: Local chemotherapy delivery platform with Nano tissue technology. Winner of the Bioentrepreneur XXI, 6th edition; Barcelona, December 2013.
Patents:
201031438. N/Ref.: 139/10 ID02054419: Predictive method of pharmacological response in Neuroblastoma. Propietaries: HSJD. Inventors: Cinzia Lavarino and Jaume Mora.

Therapeutic vaccine for diffuse intrinsic pontine glioma. Propietaries: HSJD and HCP. Inventors: Angel Montero Carcaboso, Jaume Mora, Daniel Benítez Ribas and Manel Juan Otero.

Most recent Publications:

1. D Carvalho, et al. ALK2 is a therapeutic target in ACVR1 mutant diffuse intrinsic pontine glioma. *Communications Biology 2019 (In Press)*
2. J Mora, et al. Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients. *Ped Blood Cancer 2019* Jun;66(6):e27690
3. G Pascual-Pasto, et al. Therapeutic Targeting of the RB1 Pathway in Retinoblastoma with the Oncolytic Adenovirus VCN-01. *Sci Transl Med.* 2019 Jan 23;11(476).
4. LM Guenther, et al. Targeting resistance mechanisms to CDK4/6 inhibitors with an IGF1R inhibitor drug combination strategy. *Clin Cancer Res*. 2019 Feb 15;25(4):1343-1357.
5. M Vinci, et al. Functional diversity and cooperativity between subclonal populations of paediatric glioblastoma and diffuse intrinsic pontine glioma cells. *Nature Medicine* 24, 1204–1215. 2018
6. DJ. García-Domínguez, et al. The combination of epigenetic drugs SAHA and hci-2509 synergistically inhibits Ews-Fli1 and tumor growth in Ewing sarcoma. *Oncotarget* 2018;9:31397-31410.
7. KI Pishas, et al. Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma with SP-2509 engages the endoplasmic reticulum stress response. *Mol Cancer Ther*. 2018 Sep;17(9):1902-1916.
8. A Manzanares, et al. Tissue biocompatibility of SN-38-loaded anticancer nanofiber matrices. Adv Healthc Mater. 2018 Aug;7(15):e1800255.
9. D Benitez-Ribas, et al. Immune response generated with the use of autologous dendritic cells pulsed with an allogenic tumoral cell lines lysate in patients with newly diagnosed DIPG. Front Oncol. 2018 8:127. eCollection 2018.
10. Reichardt P, et al. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: Re-evaluating the European labelling. Future Oncol. 2018 Oct;14(25):2663-2676.
11. MG Filbin, et al. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science 360, 331–335; 20 April 2018.